From left Drs. Faezeh Borzooee, Mani Larijani and Justin King, presenting a conference poster describing the AID/APOBEC small molecule inhibitors, 2022
From left Drs. Faezeh Borzooee, Mani Larijani and Justin King, presenting a conference poster describing the AID/APOBEC small molecule inhibitors, 2022 Chemotherapy is a life-saving treatment for many cancer patients. Unfortunately, many cancer drugs also cause cancer cells to mutate, which over time leads them to become more aggressive and harder to treat. SFU Molecular Biology and Biochemistry researcher Mani Larijani is exploring an unconventional approach to address this issue and improve treatment outcomes for cancer patients. -Drug resistance is a major problem in cancer treatment,- says Larijani, whose work is supported with funding from the Lotte and John Hecht Memorial Foundation. -Cancers can become resistant within months or even weeks. When this happens, treatment options can be switched, but mutations are an ongoing process, so cancer often develops multi-drug resistance.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
